Evolution of anti-HER2 therapies for cancer treatment
Sagun Parakh, Hui K Gan, Adam C Parslow, Ingrid JG Burvenich, Antony W Burgess, Andrew M Scott
Cancer Treatment Reviews | ELSEVIER SCI LTD | Published : 2017
Awarded by NHMRC
H.K. Gan has research funding from AbbVie Pharmaceuticals, is on an Advisory board for AbbVie and Merck Serono, and has received travel support/honoraria/speaker bureau for Merck Serono, AbbVie, Pfizer, Bayer, Novartis and Merck. A.M. Scott has research funding support from AbbVie Pharmaceutics and Daiichi-Sankyo Co, is an inventor of mAb806, and has a consultancy and stock ownership of Life Science Pharmaceuticals. A. Burgess is an inventor of mAb806. The authors have funding support from NHMRC [Fellowship 1084178 and Grants 1087850, 1030469, 1075898 (AMS)], Cancer Australia, Ludwig Cancer Research, John T Reid Trusts, Cure Brain Cancer Foundation, and the Victoria Cancer Agency. Funding from the Operational Infrastructure Support Program provided by the Victorian Government, Australia is also acknowledged. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.